MediQuest

MediQuest is a South Korean biotechnology company specializing in the development of next-generation therapeutics for neurodegenerative diseases using its proprietary Targeted Protein Degradation (TPD) platform. Founded in 2018, the company focuses on clearing toxic protein aggregates, such as TDP-43 and Tau, which are central to the pathology of conditions like Amyotrophic Lateral Sclerosis (ALS) and Alzheimer's disease. Its lead program, MQ-101, is a first-in-class degrader targeting TDP-43 for the treatment of ALS. MediQuest aims to overcome the limitations of traditional small molecules by directly eliminating disease-causing proteins rather than merely inhibiting them. The company has secured significant venture capital funding to advance its pipeline toward clinical trials.